A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 17
Healthy Volunteers: t
View:
• A history of 3 or more UTI episodes in the past 12 months, or 2 or more episodes in the past 6 months
• no evidence of vesicoureteral reflux or only low-grade (grade 1-2) vesicoureteral reflux
• no other genitourinary anatomical abnormality
• not receiving prophylactic antibiotics at the time of enrollment
• Ages 2-17 years.
Locations
United States
Illinois
Lurie Children's Hospital
RECRUITING
Chicago
Contact Information
Primary
Mehreen Arshad, MD
marshad@luriechildrens.org
3122274080
Time Frame
Start Date: 2022-02-02
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 35
Treatments
Experimental: Probiotic with or without antibiotic
All patients will receive probiotics for this, only those with a UTI will get ciprofloxacin.
No_intervention: Control
Patients will get standard of care treatment.
Related Therapeutic Areas
Sponsors
Leads: Ann & Robert H Lurie Children's Hospital of Chicago